Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. OliX will receive an initial payment from Lilly to complete the Phase 1 ...

(Reuters) -A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

When asked the likelihood of incretin treatments from Eli Lilly and Novo Nordisk to enter the MASH market soon, Sibold sounded unconcerned. He mentioned that 25% of those on Rezdiffra are already ...

The acquisition highlights FXR314’s commercial potential in MASH patients with combination therapy. Lilly could use FXR314 possibly with its anti-diabetic and obesity drug, tirzepatide.

We must also consider that Lilly and Novo have enormous commercial ... particularly in high-risk MASH. For now, Madrigal is tracking how prescribers are using Rezdiffra in combination with GLP ...